Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets

Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome

Rota, P. A., Oberste, M. S., Monroe, S. S., Nix, W. A., Campagnoli, R. P., Icenogle, J. P., Peñaranda, S., Bankamp, B., Maher, K., Chen, M., et al. (2003) · Science · doi:10.1126/science.1085952 · Cited by 2,477

The Genome Sequence of the SARS-Associated Coronavirus

Marra, M. A., Jones, S. J. M., Astell, C. R., Holt, R. A., Brooks-Wilson, A. R., Butterfield, Y. S. N., Khattra, J. S., Asano, J. K., Barber, S., Chan, S. Y., et al. (2003) · Science · doi:10.1126/science.1085953 · Cited by 2,027

SARS virus infection of cats and ferrets

Martina, B. E. E., Haagmans, B. L., Kuiken, T., Fouchier, R. A. M., Rimmelzwaan, G. F., van Amerongen, G., Peiris, M. J. S., Lim, W. W. L., & Osterhaus, A. D. M. E. (2003) · Nature · doi:10.1038/425915a · Cited by 571

SARS-associated viral hepatitis caused by a novel coronavirus: Report of three cases

Chau, T., Lee, K.-C., Yao, H., Tsang, T. Y. O., Chow, T., Yeung, Y.-C., Choi, K., Tso, Y.-K., Lau, T., Lai, S.-T., et al. (2004) · Hepatology · doi:10.1002/hep.20111 · Cited by 422

Compact, Synthetic, Vaccinia Virus Early/Late Promoter for Protein Expression

Chakrabarti, S., Sisler, J. R., & Moss, B. A. (1997) · BioTechniques · doi:10.2144/97236st07 · Cited by 391

Antibody‐dependent enhancement of viral infection: molecular mechanisms and in vivo implications

Takada, A., & Kawaoka, Y. (2003) · Reviews in Medical Virology · doi:10.1002/rmv.405 · Cited by 332

Monoclonal antibodies to murine hepatitis virus-4 (strain JHM) define the viral glycoprotein responsible for attachment and cell-cell fusion

Collins, A. R., Knobler, R. L., Powell, H., & Buchmeier, M. J. (1982) · Virology · doi:10.1016/0042-6822(82)90095-2 · Cited by 317

Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors

Falkner, F. G., & Moss, B. A. (1988) · Journal of Virology · doi:10.1128/jvi.62.6.1849-1854.1988 · Cited by 317

Antibody-Dependent Enhancement of Virus Infection and Disease

Cancel-Tirado, S. M., & Yoon, K. J. (2003) · Viral Immunology · doi:10.1089/088282403763635465 · Cited by 316

Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization

Vennema, H., de Groot, R. J., Harbour, D. A., Dalderup, M. J. M., Gruffydd-Jones, T., Horzinek, M. C., & Spaan, W. J. M. (1990) · Journal of Virology · doi:10.1128/jvi.64.3.1407-1409.1990 · Cited by 276

Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses

Yang, Y., Shi, W., Abiona, O. M., Nazzari, A. F., Olia, A. S., Ou, L., Phung, E., Stephens, T., Tsybovsky, Y., Verardi, R., et al. (2021) · Vaccines · doi:10.3390/vaccines9020073 · Cited by 36

Synthetic SARS-CoV-2 Spike-Based DNA Vaccine Elicits Robust and Long-Lasting Th1 Humoral and Cellular Immunity in Mice

Alamri, S. S., Alluhaybi, K. A., Alhabbab, R. Y., Basabrain, M. A., Algaissi, A. A., Almahboub, S. A., Alfaleh, M. A., Abujamel, T. S., Abdulaal, W. H., ElAssouli, M.-Z. M., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.727455 · Cited by 33

Heterologous prime-boost immunizations with chimpanzee adenoviral vectors elicit potent and protective immunity against SARS-CoV-2 infection

Liu, J., Xu, K., Xing, M., Zhuo, Y., Guo, J., Du, M., Wang, Q. M., An, Y., Li, J., Gao, P., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00360-4 · Cited by 33

Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques

Bewley, K. R., Gooch, K. E., Thomas, K. M., Longet, S., Wiblin, N. R., Hunter, L. E., Chan, K., Brown, P. J., Russell, R. A., Ho, C. M. K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg7996 · Cited by 27

Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2

Mooij, P., García‐Arriaza, J., Pérez, P., Lázaro-Frías, A., Verstrepen, B. E., Böszörményi, K. P., Mortier, D., Fagrouch, Z. C., Kiemenyi-Kayere, G., Niphuis, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845887 · Cited by 29

The Coronavirus SARS-Cov-2: the Characteristics of Structural Proteins, Contagiousness, and Possible Immune Collisions

Kharchenko, E. P. (2020) · Epidemiology and Vaccinal Prevention · doi:10.31631/2073-3046-2020-19-2-13-30 · Cited by 28

The “original antigenic sin” and its relevance for SARS-CoV-2 (COVID-19) vaccination

Rijkers, G. T., & van Overveld, F. J. (2021) · Clinical Immunology Communications · doi:10.1016/j.clicom.2021.10.001 · Cited by 27

Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us

Kumar, V. (2020) · International Reviews of Immunology · doi:10.1080/08830185.2020.1800688 · Cited by 29

A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus

Schulze, K., Staib, C., Schätzl, H. M., Ebensen, T., Erfle, V., & Guzmán, C. A. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.09.006 · Cited by 26

SARS-CoV spike protein-expressing recombinant vaccinia virus efficiently induces neutralizing antibodies in rabbits pre-immunized with vaccinia virus

Kitabatake, M., Inoue, S., Yasui, F., Yokochi, S., Arai, M., Morita, K., Shida, H., Kidokoro, M., Murai, F., Le, M. Q., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.08.039 · Cited by 23

Vaccination against SARS-CoV-2 and disease enhancement – knowns and unknowns

Zellweger, R. M., Wartel, T. A., Marks, F., Song, M., & Kim, J. H. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1800463 · Cited by 24

Development of antibody resistance in emerging mutant strains of SARS CoV‐2: Impediment for COVID‐19 vaccines

Beeraka, N. M., Sukocheva, O. A., Lukina, E., Liu, J., & Fan, R. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2346 · Cited by 23

Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT™ adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice

Lai, C.-Y., To, A., Wong, T. A. S., Lieberman, M. M., Clements, D. E., Senda, J. T., Ball, A. H., Pessaint, L., Andersen, H., Furuyama, W., et al. (2021) · Vaccine X · doi:10.1016/j.jvacx.2021.100126 · Cited by 24

IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunityPreprint

Ejemel, M., Li, Q., Hou, S., Schiller, Z. A., Wallace, A., Amcheslavsky, A., Yılmaz, N. K., Toomey, J. R., Schneider, R., Close, B. J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.15.096719 · Cited by 22

Coronaviruses Associated with the Superfamily Musteloidea

Stout, A. E., Guo, Q., Millet, J. K., de Matos, R., & Whittaker, G. R. (2021) · mBio · doi:10.1128/mbio.02873-20 · Cited by 22

Sex and age bias viral burden and interferon responses during SARS-CoV-2 infection in ferrets

Francis, M. E., Richardson, B., Goncin, U., McNeil, M., Rioux, M. L., Foley, M. K., Ge, A., Pechous, R. D., Kindrachuk, J., Cameron, C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93855-9 · Cited by 22

Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs

Ishii, K., Hasegawa, H., Nagata, N., Mizutani, T., Morikawa, S., Suzuki, T., Taguchi, F., Tashiro, M., Takemori, T., Miyamura, T., et al. (2006) · Virology · doi:10.1016/j.virol.2006.03.020 · Cited by 21

Progress of Middle East respiratory syndrome coronavirus vaccines: a patent review

Choi, J., Kim, M.-G., Oh, Y., & Kim, Y. B. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1281248 · Cited by 20

Coronavirus as silent killer: recent advancement to pathogenesis, therapeutic strategy and future perspectives

Aran, K. R., Rohit, Ghosh, A., & Singh, S. (2020) · VirusDisease · doi:10.1007/s13337-020-00580-4 · Cited by 20

SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines

Velusamy, P., Kiruba, K., Su, C., Arun, V., Anbu, P., Gopinath, S. C. B., & Vaseeharan, B. (2021) · Journal of King Saud University - Science · doi:10.1016/j.jksus.2021.101648 · Cited by 20

An overview of Middle East respiratory syndrome coronavirus vaccines in preclinical studies

Zhang, N., Shang, J., Li, C., Zhou, K., & Du, L. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1813574 · Cited by 18

Viral codon optimization on SARS‐CoV‐2 Spike boosts immunity in the development of COVID‐19 mRNA vaccines

Lai, C., Kim, D.-K., Kang, S., Li, K., Cha, I., Sasaki, A., Porras, J., Xia, T., & Jung, J. U. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29183 · Cited by 17

Adjuvant-dependent impact of inactivated SARS-CoV-2 vaccines during heterologous infection by a SARS-related coronavirus

Dillard, J. A., Taft-Benz, S., Knight, A. C., Anderson, E. J., Pressey, K. D., Parotti, B., Martinez, S. A., Diaz, J., Sarkar, S., Madden, E. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47450-x · Cited by 16

Biomaterials Made from Coiled-Coil Peptides

Conticello, V. P., Hughes, S. A., & Modlin, C. (2017) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-319-49674-0_17 · Cited by 16

A review on epidemiology, genomic characteristics, spread, and treatments of COVID-19

Bharati, S., Podder, P., Mondal, M. R. H., Podder, P., & Köse, U. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90769-9.00011-6 · Cited by 16

The virus that shook the world: questions and answers about SARS-CoV-2 and COVID-19

Alexandrova, R., Beykov, P., Vassilev, D. I., Jukič, M., & Podlipnik, Č. (2020) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2020.1847683 · Cited by 16

Novel coronavirus SARS-CoV-2 in the context of global epidemiology of coronavirus infections

Васильевич, С. М. (2020) · Journal of NBC Protection Corps · doi:10.35825/2587-5728-2020-4-1-32-65 · Cited by 15

Prime-Pull Immunization of Mice with a BcfA-Adjuvanted Vaccine Elicits Sustained Mucosal Immunity That Prevents SARS-CoV-2 Infection and Pathology

Shamseldin, M. M., Zani, A., Kenney, A., Evans, J. P., Zeng, C., Read, K. A., Caution, K., Hall, J. M., Brown, J. M., Gunsch, G., et al. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200297 · Cited by 16

New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection

Bauso, L. V., Imbesi, C., Gasparo, I., Calì, G., & Bitto, A. (2021) · Pharmaceuticals · doi:10.3390/ph14060503 · Cited by 13

Applying Immune Instincts and Maternal Intelligence from Comparative Microbiology to COVID-19

Cimolai, N. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00634-0 · Cited by 11

COVID-19 mitigation: nanotechnological intervention, perspective, and future scope

Adhikari, A., Mandal, D., Rana, D. K., Nath, J., Bose, A., Sonika, S., Orasugh, J. T., De, S., & Chattopadhyay, D. (2022) · Materials Advances · doi:10.1039/d2ma00797e · Cited by 12

Newly Emerging Human Coronaviruses: Animal Models and Vaccine Research for SARS, MERS, and COVID-19

Lee, P., & Kim, D.-J. (2020) · Immune Network · doi:10.4110/in.2020.20.e28 · Cited by 12

A CFD study of the transport and fate of airborne droplets in a ventilated office: The role of droplet-droplet interactions

Gomez-Flores, A., Hwang, G., Ilyas, S., & Kim, H. (2021) · Frontiers of Environmental Science & Engineering · doi:10.1007/s11783-021-1465-8 · Cited by 11

The Use of Non-Human Primates in Biological and Medical Research: Evidence Submitted by FRAME to the Academy of Medical Sciences/Medical Research Council/Royal Society/Wellcome Trust Working Group

Bhogal, N., Hudson, M., Balls, M., & Combes, R. D. (2005) · Alternatives to Laboratory Animals · doi:10.1177/026119290503300501 · Cited by 10

SARS-CoV Spike Proteins Expressed by the Vaccinia Virus Tiantan Strain: Secreted SQ Protein Induces Robust Neutralization Antibody in Mice

Yan, K., Tan, W., Wang, H., Wang, Y., Zhang, X., Li, Y., & Ruan, L. (2009) · Viral Immunology · doi:10.1089/vim.2008.0064 · Cited by 9

Recombinant Live Vaccines to Protect Against the Severe Acute Respiratory Syndrome Coronavirus

Enjuanes, L., Nieto-Torres, J. L., Jiménez-Guardeño, J. M., & DeDiego, M. L. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0277-8_4 · Cited by 9

Mit Immanuel Kant in die zweite Welle der gegenwärtigen Pandemie

Weigl, J. A. I. (2020) · Prävention und Gesundheitsförderung · doi:10.1007/s11553-020-00783-z · Cited by 8

Threading the Pieces Together: Integrative Perspective on SARS-CoV-2

Kanakan, A., Mishra, N., Vasudevan, J. S., Sahni, S., Khan, A., Sharma, S., & Pandey, R. (2020) · Pathogens · doi:10.3390/pathogens9110912 · Cited by 8

The status of COVID-19 vaccines in India: A review

Jha, D. K., Pranay, K., Samiksha, Kumar, A., & Yashvardhini, N. (2023) · Vacunas (English Edition) · doi:10.1016/j.vacun.2023.04.003 · Cited by 12

A dossier on COVID-19 chronicle

Rufaida, R., Mahmood, T., Kedwai, I., Ahsan, F., Shamim, A., Shariq, M., & Parveen, S. (2021) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2020-0511 · Cited by 8

Molecular Mimicry Map (3M) of SARS-CoV-2: Prediction of potentially immunopathogenic SARS-CoV-2 epitopes via a novel immunoinformatic approachPreprint

An, H., & Park, J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.12.344424 · Cited by 7

Recombinant subunits of SARS‐CoV‐2 spike protein as vaccine candidates to elicit neutralizing antibodies

ghahroodi, F. N., Khalili, S., & Rasaee, M. J. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24328 · Cited by 5

Potential Challenges for Coronavirus (SARS-CoV-2) Vaccines Under Trial

Usmani, S. S., & Raghava, G. P. S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.561851 · Cited by 6

Vaccine development for zoonotic viral diseases caused by positive‑sense single‑stranded RNA viruses belonging to the Coronaviridae and Togaviridae families (Review)

Babaeimarzangou, S. S., Zaker, H., Soleimannezhadbari, E., Shamsi-Gamchi, N., Kazeminia, M., Tarighi, S., Seyedian, H., Tsatsakis, A. M., Spandidos, D. A., & Margina, D. M. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11741 · Cited by 5

Strategies for Designing Peptide Immunogens To Elicit α-Helical Conformation-Specific Antibodies Reactive with Native Proteins

Yan, Z., Hartsock, W. J., Qian, Z., Holmes, K. V., & Hodges, R. S. (2012) · ACS symposium series · doi:10.1021/bk-2012-1095.ch006 · Cited by 5

Male sex and age biases viral burden, viral shedding, and type 1 and 2 interferon responses during SARS-CoV-2 infection in ferretsPreprint

Francis, M. E., Richardson, B., McNeil, M., Rioux, M. L., Foley, M. K., Ge, A., Pechous, R. D., Kindrachuk, J., Cameron, C., Richardson, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.12.426381 · Cited by 5

No evidence for enhanced disease with human polyclonal SARS-CoV-2 antibody in the ferret model

Reed, D. S., McElroy, A. K., Barbeau, D. J., McMillen, C. M., Tilston-Lunel, N. L., Nambulli, S., Cottle, E., Gilliland, T. C., Rannulu, H., Lundy, J. D., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0290909 · Cited by 3

SARS Coronavirus Pathogenesis and Therapeutic Treatment Design

Sheahan, T. P., & Baric, R. S. (2009) · Springer eBooks · doi:10.1007/978-3-642-03683-5_13 · Cited by 4

HOW PREPARED ARE WE TO CONTROL SEVERE ACUTE RESPIRATORY SYNDROME IN FUTURE

Bhardwaj (2013) · Current Research in Virology · doi:10.3844/ajvsp.2013.8.19 · Cited by 3

The mutation features and geographical distributions of the surface glycoprotein (S gene) in SARS‐CoV‐2 strains: A comparative analysis of the early and current strains

Liu, R., Lin, X., Chen, B., Hou, Z., Zhang, Q., Lin, S., Geng, L., Sun, Z., Cao, C., Shi, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28023 · Cited by 3

Coronavirus - Drug Discovery and Therapeutic Options

Tayyab, A. S., Qurban, M., Mazhar, M., Tayyab, Z., Tahir, M., & Tayyab, Z. (2021) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2021/v33i50a33391 · Cited by 2

Design and Immunogenicity of SARS-CoV-2 DNA Vaccine Encoding RBD-PVXCP Fusion Protein

Dormeshkin, D., Katsin, M., Stegantseva, M. V., Golenchenko, S., Shapira, M. A., Dubovik, S., Lutskovich, D. V., Kavaleuski, A., & Meleshko, A. (2023) · Vaccines · doi:10.3390/vaccines11061014 · Cited by 3

The Novel Coronavirus Disease-COVID-19: Pandemic and Its Impact on Environment

Gautam, M., Kumari, S., Gautam, S., Singh, R. K., & Kureel, R. S. (2020) · Current Journal of Applied Science and Technology · doi:10.9734/cjast/2020/v39i1730748 · Cited by 2

Community-acquired pneumonia: paving the way towards new vaccination concepts

Becker, P. D., & Guzmán, C. A. (2007) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-7563-8_10 · Cited by 1

Understanding COVID-19, Genome, Epidemiology, Diagnosis, Treatment, and Vaccination

Mostafa, E., El-Sawah, A., Magdy, E., Sayed, A., El-Azab, S., Natei, A., Husein, A., Hassan, S., Mostafa, M., & Omran, M. M. (2020) · Journal of Bioscience and Applied Research/Journal of Bioscience and Applied Research · doi:10.21608/jbaar.2020.106102 · Cited by 1

Development and Identification of Stably BHK-21 Cell Lines Expressing T7 RNA Polymerase

Zhuang, D., LianZhi, M., Sun, Y., Huang, Z., Cong, Y., Wang, G., & ., L. S. (2012) · Journal of Animal and Veterinary Advances · doi:10.3923/javaa.2012.1316.1321 · Cited by 1

CORONAVIRUS VACCINE DEVELOPMENT: FROM SARS AND MERS TO COVID-19 (RUSSIAN TRANSLATION)

Li, Y.-D., Chi, W.-Y., Su, J.-H., Ferrall, L., Hung, C., & Wu, T. ‐. (2020) · Juvenis scientia · doi:10.32415/jscientia_2020_6_6_41-80 · Cited by 1

Antiviral Agents for SARS

Hayden, F. G., & Denison, M. R. (2005) · Wiley eBooks · doi:10.1002/9780470755952.ch20 · Cited by 1

Subunit Vaccine Against Sars-Cov-2 Using CTL and HTL EpitopesPreprint

zahra, L., & Khan, Y. D. (2021) · ChemRxiv · doi:10.26434/chemrxiv.14447016.v1 · Cited by 1

Development and Preclinical Evaluation of Virus Like Particle Vaccine Against COVID-19 InfectionPreprint

Ismail Yilmaz, C., İpekoğlu, E. M., Bulbul, A., Turay, N., Yıldırım, M., Evcili, İ., Yilmaz, N. S., Aydin, Y., Guvencli, N., Gungor, B., et al. (2021) · doi:10.22541/au.162615692.26217047/v2 · Cited by 1

Development and Preclinical Evaluation of Virus Like Particle Vaccine Against COVID-19 InfectionPreprint

Ismail Yilmaz, C., İpekoğlu, E. M., Bulbul, A., Turay, N., Yıldırım, M., Evcili, İ., Yilmaz, N. S., Aydin, Y., Guvencli, N., Gungor, B., et al. (2021) · doi:10.22541/au.162615692.26217047/v1 · Cited by 1

Development of SARS-COV therapeutics using quaternary protein mimetics

Neo, T. L. (2009) · doi:10.32657/10356/41875

[Progress and analysis on the development of 2019-nCoV vaccine].

Kang, Z., & Tang, M. (2020) · PubMed Central · doi:10.7507/1001-5515.202004025

Characterization of recombinant Modified Vaccinia virus Ankara for delivery of Middle East Respiratory Syndrome Coronavirus spike protein antigens

Song, F. (2014) · doi:10.5282/edoc.17246

COVID19: Exploring uncommon epitopes for a stable immune response through MHC1 bindingPreprint

Abitogun, F., Srivastava, R., Sharma, S., Komarysta, V., Akurut, E., Munir, N., Macalalad, L. S., Olawale, O., Owolabi, O., Abayomi, G. O., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.14.339689

Overview of SARS-CoV-2 Outbreak and Potential Therapeutic Strategies

Eldalal, O., Oyebanji, O. A., Thapa, P., & Oroszi, T. L. (2020) · Global Journal of Health Science · doi:10.5539/gjhs.v12n13p95

Enhanced immunogenicity of a synthetic DNA vaccine expressing consensus SARS-CoV-2 Spike protein using needle-free immunizationPreprint

Alamri, S. S., Alluhaybi, K. A., Alhabbab, R. Y., Algaissi, A. A., Almahboub, S. A., Alfaleh, M. A., Abujamel, T. S., Abdulaal, W. H., ElAssouli, M.-Z. M., Alharbi, R. H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.01.429219

Neuromodulatory effects of SARS-CoV2 infection: Possible therapeutic targets

Kumar, S., Shanker, O. R., Kumari, N., Tripathi, M., Chandra, P. S., Dixit, A. B., & Banerjee, J. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1953475

COVID19 Pandemic and Children

Yıldız, S., Toros, S. Z., & Rombaux, P. (2021) · Springer eBooks · doi:10.1007/978-3-030-80691-0_68

Hydroxychloroquine (HCQ) Exhibits Better Binding to the Main Protease (Mpro) Compared to Spike Protein (S protein) of SARS-CoV-2: An In-silico Analysis

Reddy, B. D., Tulimilli, S. V., Durai Ananda Kumar, T., Chitturi, C. K., Bettadapura, A. D. S., Natraj, S. M., & Madhunapantula, S. V. (2021) · Clinical Cancer Drugs · doi:10.2174/2212697x08666211210103711

Coronavirus - Drug Discovery and Therapeutic Drug Monitoring Options

Ahmad, K. A., Nizami, S. A., & Ghous, M. H. (2022) · Pharmaceutics and Pharmacology Research · doi:10.31579/2693-7247/044

Prime-pull immunization of mice with a BcfA-adjuvanted vaccine elicits mucosal immunity and prevents SARS CoV-2 infection and pathologyPreprint

Shamseldin, M. M., Zani, A., Kenney, A. D., Evans, J., Zeng, C., Read, K. A., Caution, K., Hall, J. M., Brown, J. M., Gunsch, G., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.06.487394

Subunit Vaccine Against Sars-Cov-2 Using CTL and HTL EpitopesPreprint

zahra, L., & Khan, Y. D. (2021) · ChemRxiv · doi:10.26434/chemrxiv.14447016

SARS-CoV-2 infection: Pathogenesis, Immune Responses, Diagnosis

Malviya, K. K. (2022) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.16.3.20

The Rationale Behind the Effectiveness of COVID-19 Vaccines and Associated Immunological Mechanisms

Khatib, S. E. (2022) · Turkish Journal of Immunology · doi:10.4274/tji.galenos.2022.55264

No evidence for enhanced disease with polyclonal SARS-CoV-2 antibody in the ferret modelPreprint

Reed, D., McElroy, A. K., Barbeau, D. J., McMillen, C. M., Tilston-Lunel, N. L., Nambulli, S., Cottle, E., Gilliland, T. C., Rannulu, H., Lundy, J. D., et al. (2023) · bioRxiv · doi:10.1101/2023.08.19.553970

Study of HRCT Score, Comorbidities, Specific Blood Findings, and Management of COVID-positive Patients at Dr DY Patil Medical College and Hospital, Pune

Rajashekhar, R. P., Dashora, R., Mahajan, G. D., & Sur, A. N. (2024) · Otorhinolaryngology Clinics - An International Journal · doi:10.5005/jp-journals-10003-1452

Role of phytochemicals in combating corona - virus infection: A review

Ahmed, M. S., Rawani, A., Gope, A., & Khanrah, J. (2024) · Notulae Scientia Biologicae · doi:10.55779/nsb16411869

Vaccine-Associated Enhanced Respiratory Disease: From Animal Models to Human Health

Dillard, J. A., Saldivar, R. A., Heise, M. T., & Baxter, V. K. (2026) · Vaccines · doi:10.3390/vaccines14090799

Immunization with Modified Vaccinia Virus Ankara-Based Recombinant Vaccine against Severe Acute Respiratory Syndrome Is Associated with Enhanced Hepatitis in Ferrets

Weingartl, H. M., Czub, M., Czub, S., Neufeld, J., Marszal, P., Gren, J., Smith, G. A., Jones, S. E., Proulx, R., Deschambault, Y., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.22.12672-12676.2004 · Cited by 344

Severe Acute Respiratory Syndrome Coronavirus Infection in Vaccinated Ferrets

Darnell, M. E. R., Plant, E. P., Watanabe, H., Byrum, R., Claire, M. S., Ward, J. M., & Taylor, D. R. (2007) · The Journal of Infectious Diseases · doi:10.1086/522431 · Cited by 54

Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines

See, R. H., Petric, M., Lawrence, D. J., Mok, C. P. Y., Rowe, T., Zitzow, L. A., Karunakaran, K. P., Voss, T. G., Brunham, R. C., Gauldie, J., et al. (2008) · Journal of General Virology · doi:10.1099/vir.0.2008/001891-0 · Cited by 85

1092. Adenovirus-Based Vaccine Prevents Pneumonia in Ferrets Challenged with the SARS Coronavirus

(2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.639 · Cited by 1

Recombinant Modified Vaccinia Virus Ankara Expressing the Spike Glycoprotein of Severe Acute Respiratory Syndrome Coronavirus Induces Protective Neutralizing Antibodies Primarily Targeting the Receptor Binding Region

Chen, Z., Zhang, L., Qin, C., Ba, L., Yi, C. E., Zhang, F., Wei, Q., Tian, H., Yu, W., Yu, J., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.5.2678-2688.2005 · Cited by 181